“For the first time, we’re able to give close to 100% of women an answer as to their risk, whether it’s positive or negative for BRCA1 or one of the other dominant susceptibility alleles, More importantly, for those 90% of women who receive a negative genetic test, they now have an answer to their quantifiable risk that enables them to take proactive measures to either diminish their risk for developing a cancer or to identify that cancer at an early and more curable stage.”

Jonathan M. Lancaster

Dr. Ora Gordon discusses hereditary cancer testing, and how riskScore is transformative in terms of breast cancer risk assessment.